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http://dx.doi.org/10.1016/j.ccr.2014.02.005SUMMARYTumor endothelial cells (ECs) promote cancer progression in ways beyond their role as conduits supporting
metabolism. However, it is unknown how vascular niche-derived paracrine factors, defined as angiocrine fac-
tors, provoke tumor aggressiveness. Here, we show that FGF4 produced by B cell lymphoma cells (LCs)
through activating FGFR1 upregulates the Notch ligand Jagged1 (Jag1) on neighboring ECs. In turn, upregu-
lation of Jag1 on ECs reciprocally induces Notch2-Hey1 in LCs. This crosstalk enforces aggressive CD44+
IGF1R+CSF1R+ LC phenotypes, including extranodal invasion and chemoresistance. Inducible EC-selective
deletion of Fgfr1 or Jag1 in the Em-Myc lymphoma model or impairing Notch2 signaling in mouse and human
LCs diminished lymphoma aggressiveness and prolonged mouse survival. Thus, targeting the angiocrine
FGF4-FGFR1/Jag1-Notch2 loop inhibits LC aggressiveness and enhances chemosensitivity.INTRODUCTION
Vascular endothelial cells (ECs) are a specialized component of
the tumor microenvironment that can orchestrate tumor growth
and invasion (Beck et al., 2011; Bergers and Hanahan, 2008;
Butler et al., 2010a; Calabrese et al., 2007; Carmeliet and Jain,
2011; Charles et al., 2010; Ghajar et al., 2013; Lu et al., 2013;
Weis and Cheresh, 2011). During regeneration, tissue-specific
ECs provide instructive paracrine cues, known as angiocrine
growth factors, that trigger proliferation of repopulating progen-
itor cells (Brantley-Sieders et al., 2011; Butler et al., 2010a,
2010b, 2012; Ding et al., 2014, 2010, 2011, 2012; PotenteSignificance
Blood vessels within lymphomas are not just passive conduits
tute a maladapted niche actively instigating aggressiveness
supply angiocrine factors to promote chemotherapy resista
LCs. LCs produce FGF4 to induce expression of Notch ligand
Notch2 in LCs to promote tumor invasiveness and chemores
LCs and ECs decreases tumor progression and promotes s
tumor-bearing mice. Targeting protumorigenic angiocrine fac
cious approaches to block tumorigenesis and restore chem
perfusion.
350 Cancer Cell 25, 350–365, March 17, 2014 ª2014 Elsevier Inc.et al., 2011; Red-Horse et al., 2007). However, the mechanism
by which EC-derived angiocrine factors influence tumor behav-
iors is unknown (Gilbert and Hemann, 2010; Leite de Oliveira
et al., 2012; Nakasone et al., 2012; Schmitt et al., 2000).
Notch signaling is a pivotal modulator of lymphomagenesis
(Aster et al., 2008; Espinosa et al., 2010; Liu et al., 2010; Lobry
et al., 2013), enhancing Myc activity and upregulating receptors
such as insulin growth factor-1 receptor (IGF1R) (Medyouf et al.,
2011; Weng et al., 2006). The Jagged (Jag) and Delta-like (Dll)
families of Notch ligands induce Notch signaling (Gridley, 2010;
Siekmann and Lawson, 2007). Both Jag1 and Dll4 are preferen-
tially expressed by ECs during tumor progression but havedelivering nutrients but contain specialized ECs that consti-
during tumor progression. Here, we show that tumor ECs
nce and extranodal invasiveness of CD44+IGF1R+CSF1R+
Jag1 in ECs. In turn, EC-derived angiocrine Jag1 activates
istance. Interfering with the FGF4/Jag1 cross-talk between
ensitivity to chemotherapy, thereby increasing survival of
tors supplied by lymphoma blood vessels promises effica-
otherapy sensitivity without compromising tumor blood
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thi et al., 2011; Vilimas et al., 2007). Dll4 is expressed by sprout-
ing ECs and appears to regulate EC expansion (proliferative
angiogenesis), whereas juxtacrine activation of Notch
receptors on tumor cells appears to be mediated by EC-derived
Jag1 (inductive angiogenesis) (Lu et al., 2013; Sonoshita et al.,
2011; Noguera-Troise et al., 2006; Ridgway et al., 2006). Howev-
er, mechanisms controlling expression of these Notch ligands in
tumor ECs are undefined (Benedito et al., 2009; Corada et al.,
2010; High et al., 2008; Hoey et al., 2009; Hofmann et al.,
2010; Tung et al., 2012). Moreover, the paucity of EC-
specific mouse genetic models has handicapped elucidation of
the EC-derived angiocrine signals regulating the fate and
behavior of tumors.
Malignant lymphoma cells (LCs) are composed of heteroge-
neous cell subpopulations, with a subset of LCs possessing
more aggressive features (Dierks et al., 2007; Hoey et al.,
2009; Kelly et al., 2007). Although chemotherapy eliminates the
majority of proliferating LCs, a subpopulation of aggressive
LCs manifests resistance, ultimately leading to lymphoma
relapse. Because the surrounding microenvironment can sup-
port tumor cells (Hanahan and Coussens, 2012; Lane et al.,
2009; Memarzadeh et al., 2007; Rakhra et al., 2010; Reimann
et al., 2010; Scadden, 2012; Trimboli et al., 2009; Zhang et al.,
2012), we reasoned that elucidating the microenvironmental sig-
nals (i.e., tumor vascular niche) influencing aggressive LCs, such
as lymphoma initiating cells (LICs), could provide effective lym-
phoma treatment strategies.
RESULTS
ECs Support Expansion of LCswith Aggressive Features
To identify the crosstalk between ECs and LCs without the
confounding influence of supplementation with exogenous
serum and angiogenic growth factors, we devised a serum-
and growth factor-free platform to propagate LCs in coculture
with ECs. To this end, we transduced ECs, such as human
umbilical vein ECs, with the adenoviral E4ORF1 gene. E4ORF1
transduced ECs (VeraVec ECs)—for simplicity referred to here
as ECs—are nontransformed but have low-level Akt signaling
that permits their serum-free survival while retaining their tis-
sue-specific vascular attributes as well as the capacity to form
functional contact-inhibited monolayers in vitro and perfused,
patent blood vessels in vivo (Butler et al., 2010b, 2012; Nolan
et al., 2013; Seandel et al., 2008). Indeed, because maintenance
of VeraVec ECs does not require recombinant angiogenic factors
(e.g., vascular endothelial growth factor A (VEGF-A) and fibro-
blast growth factor 2 (FGF2)), serum, or other xenobiotic factors,
these ECs can be used in coculture models to screen and to
identify the instructive vascular niche-like functions and angio-
crine factors supporting the expansion of organ-specific stem
and progenitor cells (Butler et al., 2010b; Ding et al., 2010,
2011, 2014) and possibly tumor cells. To reveal the angiocrine
influence of ECs on LCs, we compared expansion of
B220+CD19+ LCs isolated from Em-Mycmice in three conditions:
in serum-containing medium (LCSerum), in serum- and growth
factor-free medium (LC), or in serum- and growth factor-free
medium with cocultured ECs (LCEC). We found that serum-free
coculture of LCs with ECs supported greater LC proliferationthan serum alone (Figures 1A and 1B; Figures S1A and S1B
available online). Subcutaneous coinjection of LCs with ECs
into immunodeficient NOD-SCID-IL2Rg/ (NSG) mice signifi-
cantly enhanced tumor growth, compared with LCs injected
alone (Figure S1C). The growth rate of LCEC in wild-type (WT)
C57/B6 mice was significantly higher than LCSerum early after
subcutaneous injection (Figures S1D and S1E). We then
assessed the serial methylcellulose colony formation (MCF)
capacity of expanded LCs. LCEC had 5-fold greater MCF poten-
tial than did LCSerum (Figures 1C and 1D). Limiting dilution trans-
plantation into NSG mice showed that LCEC cells contained
more lethal LCs than did LCSerum cells (Figure 1E). Thus, ECs
establish an inductive vascular niche that enforces outgrowth
of aggressive LCs.
We then evaluated whether ECs could confer chemotherapy
resistance to LCs by treating LCEC and LCSerumwith doxorubicin.
Indeed, LCEC were less sensitive to doxorubicin than LCSerum
in vitro (Figures 1F and 1G). Doxorubicin prolonged survival of
NSG mice transplanted with LCSerum but not mice transplanted
with LCEC (Figure 1H). Thus, coculture with ECs promoted a che-
moresistant phenotype in the B220+CD19+Myc+ B cell LCs.
To investigate the mechanism underlying the aggressiveness
of LCEC, we profiled the transcriptome of LCEC. Coculture with
ECs induced transcripts characteristic of LICs, including CD44,
IGF1R, and CSF1R (Hanahan and Weinberg, 2011; Medyouf
et al., 2011) (Figure 1I; Table S1). Flow cytometry analysis and
quantitative PCR (qPCR) confirmed that EC coculture-mediated
upregulation of corresponding proteins was due to generation of
a CD44+IGF1R+CSF1R+ LC subset (Figures 1J, S1F, and S1G).
To assess the functional activity of the CD44+IGF1R+CSF1R+
subpopulation, we obtained clonally derived LCs by serial
dilution in coculture with ECs (Figure 1K) and compared their
activity to CD44IGF1RCSF1R LCs. The CD44+IGF1R+
CSF1R+ LCs yielded more serial methylcellulose colonies,
caused higher lethality in limiting dilution transplantation, and
were less sensitive to doxorubicin than CD44IGF1RCSF1R
LCs (Figures 1L–1O and S1H–S1J). Thus, EC coculture enabled
outgrowth of more aggressive and chemoresistant CD44+
IGF1R+CSF1R+ LCs.
ECs Support LCs via Jag1-Dependent Juxtacrine
Activation of Notch2 Pathway
We next investigated the mechanism by which ECs stimulate
aggressiveness in LCs. Transcription profiling showed upregula-
tion of the Notch downstream transcriptional effector Hey1 in
LCEC (Figure 1I). qPCR confirmed specific upregulation of
Hey1 in LCEC (Figure 2A) and in the aggressive CD44+IGF1R+
CSF1R+ LC subpopulation (Figures S2A– S2C). To test whether
Hey1 upregulation confers aggressive LC features, we studied
how loss and gain of function of Notch1, Notch2, and Hey1 in
LCs altered their expansion (Figures 2B and S2D–S2F). Genetic
silencing using small hairpin RNA (shRNA) to Notch2 (shNotch2)
or Hey1 (shHey1), but not Notch1 (shNotch1), abrogated EC-
driven expansion of LCs. In contrast, Hey1 overexpression phe-
nocopied the effect of EC coculture (Figures 2C, 2D, S2G, and
S2H). Notch pathway inhibition using the g-secretase inhibitor
compound E similarly abrogated LC growth after coculture
with ECs. Immunoblot and immunostaining for Notch intra-
cellular domains and chromatin immunoprecipitation (ChIP) ofCancer Cell 25, 350–365, March 17, 2014 ª2014 Elsevier Inc. 351
Figure 1. Expansion of Myc+ LCs with Aggressive LIC Features after Coculture with ECs in Serum and Cytokine-free Conditions
(A) Representative images of Em-Myc mouse LCs cultured with EC. Scale bar, 200 mm.
(B) Quantification of LC number of Em-Mycmouse LCs cultured in the absence of ECs (LC), with EC (LCEC), or with serum supplementation (LCSerum). *p < 0.02;
n = 5. All data are presented as means ± SEM throughout.
(C and D) Representative image (C) and the colony number (D) of colony-forming capacity of LCs after serial passage. Five clones were passed every step. *p <
0.02. Scale bar, 500 mm.
(E) Survival curve of NSG mice i.p. transplanted with the indicated numbers of LCs; n = 6–8.
(F and G) Quantification (F) and representative image (G) of proliferation of LCs after treatment of indicated concentrations of doxorubicin; n = 5. Scale bar,
1,000 mm.
(H) Survival of NSG mice inoculated with 1 3 105 indicated LCs and treated or not treated with doxorubicin (chemo) as indicated; n = 6–8.
(I) Heat map presenting the expression level of indicated transcripts in LCEC and LCSerum.
(legend continued on next page)
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LCEC (Figures 2E, 2G, S2I, and S2J). Therefore, coculture with
ECs selectively activates Notch2 in LCs, resulting in Hey1-
dependent expansion of LCs.
Next, we tested how disruption of Notch signaling affected
in vivo hepatic tumor seeding following intrasplenic injection
(Ding et al., 2010) (Figure 2H). Knockdown of Notch2 or Hey1 or
administrationof compoundEsignificantly reducedhepatic tumor
load, but Notch1 knockdownhad little effect (Figures 2I, 2-K, S2K,
and S2L). Thus, juxtacrine activation of Notch2-Hey1 by ECs pro-
motes extranodal invasion, a feature of aggressive lymphomas.
Although ECs express several Notch ligands, Jag1 was pri-
marily upregulated by ECs after coculture with LCs (Figure 2L).
This finding implicates EC Jag1 as the ligand activating Notch2
in LCs because LCs express negligible Jag1 (Figure S2M). To
test this, we knocked down Jag1 in ECs (ECshJag1) and cocul-
tured these feeder cells with Myc+ LCs expressing a Notch
reporter (RBPJ-driven GFP). ECshJag1 were less effective than
control ECs transduced with scrambled shRNA (ECSrb) in sup-
porting serum- and growth factor-free expansion of LCs and in
inducing Hey1 upregulation and Notch activation (Figures 2M–
2P). Notably, inhibition of the Notch2-Hey1 pathway in CD44+
IGF1R+ LCs after coculture with ECs had little effect on the
aggressive feature (Figures S2N and S2O). Thus, propagation
of aggressive LICs in vitro is driven by EC Jag1 expression.
EC-Specific Upregulation of Jag1 in Human Lymphoma
Tissue Accompanies Propagation of Perivascularly
Localized Aggressive LCs
To investigate whether human LCs upregulate Jag1 in ECs, we
stained primary human Burkitt’s lymphoma sections for Jag1
and Hey1. Jag1 was specifically expressed by tumor ECs but
not by LCs in all tested lymphomas (Figures 3A and 3B; Fig-
ure S3A and Table S2). Notably, Hey1 was preferentially ex-
pressed in LCs adjacent to Jag1+ tumor ECs (Figures 3A and
3C). We next investigated whether ECs foster propagation of
human Burkitt’s LCs that harbor a translocated MYC gene under
the control of immunoglobulin heavy chain gene regulatory
elements, as modeled by the Em-Myc+ mouse. Coculture of
CD19+ human Burkitt’s LCs with ECs triggered Notch2-medi-
ated signaling in LCs and outgrowth of the CD44+IGF1R+ sub-
population (Figures 3D–3F and S3B–S3F). Expansion of human
lymphoma colony-forming cells and hepatic lymphoma load
was also promoted by coculture with ECs, compared with serum
culture (Figures 3G–3J). Disruption of the Notch2-Hey1 pathway
during coculture by knockdown of Jag1 in ECs (ECshJag1) or
Notch2 in LCs (LCshNotch2) or use of compound E abrogated
EC-dependent expansion, colony formation, and extranodal
invasiveness of human LCs (Figures 3G–3N and S3G–S3J).(J) Representative flow cytometry graph of CD44 and IGF1R expression in LCs.
(K) Representative time-lapse microscopy image of single colony expansion of
IGF1R+CSF1R+ LCs (bottom panel). Scale bar, 25 mm.
(L andM) Serial colony forming ability (L) and growth inhibition after doxorubicin tre
*p < 0.025; n = 4.
(N) Tumorigenicity of indicated LCs was compared by limiting dilution tran
CD44IGF1RCSF1R LC-injected groups, respectively.
(O) Survival of NSG mice implanted with 105 indicated LCs and then treated with
See also Figure S1 and Table S1.Notably, after intrasplenic injection into NSG mice, human
LCEC induced Jag1 expression in the ECs surrounding the lym-
phoma nodules but not tumor-free hepatic regions (Figure 3O).
Thus, expansion of invasive human Burkitt’s LCs is also driven
by instructive angiocrine factors supplied by the vascular niche.
LCs Induce FGFR1 Signaling in ECs to Prime a Jag1+
Vascular Niche that Reciprocally Reinforces Lymphoma
Propagation and Chemoresistance
We have found that during organ regeneration, activation of
VEGF-A/VEGFR2 and FGF/FGF receptor 1 (FGFR1) signaling in
ECs induces expression of angiocrine factors (Ding et al.,
2010, 2011, 2014). Hence, we tested whether LCs might co-
opt these mechanisms to upregulate Jag1 in tumor ECs and
form a malignant vascular niche. Both microarray expression
and qPCR analysis showed that coculture with ECs upregulated
FGF4 in mouse and human LCs (Figure 4A). Whereas normal
human lymph nodes have negligible FGF4, we found significant
expression of FGF4 protein in human Burkitt’s lymphoma tissue
and preferential activation of FGFR1 in the lymphoma-asso-
ciated ECs (Figure S4A). To examine whether FGFR1-mediated
signaling in ECs was necessary for Jag1 induction, we exposed
control ECs and FGFR1-deficient ECs to serum-free or con-
ditioned media (CM) derived from LCs. CM derived from mouse
LCEC activated Jag1 expression in ECs in a FGFR1-dependent
manner (Figures 4B and 4C). Notably, during EC-LC coculture,
shRNA knockdown of FGFR1 in ECs or of FGF4 in LCs blocked
Jag1 induction and FGFR1 signaling in ECs (Figures 4D and
S4B–S4D). Importantly, after intrasplenic injection, FGF4-
deficient human LCs failed to upregulate Jag1 in the ECs of liver
lymphoma nodules of recipient mice (Figure 4E). Therefore,
LCs supply FGF4 to activate FGFR1 on ECs to reinforce Jag1--
mediated vascular niche function, driving Notch2-dependent
expansion of aggressive LCs.
To determine whether this ‘‘feed-forward’’ loop drives lym-
phoma tumorigenesis in vivo,we conditionally deleted Fgfr1 spe-
cifically in adult ECs by crossing VE-cadherin-CreERT2 mice with
Fgfr1loxP/loxP mice (Figure 4F) and using tamoxifen to delete Fgfr1
specifically in ECs (Fgfr1iDEC/iDEC) (Figures S4E and S4F). To con-
trol for Cre-mediated toxicity, we used EC-specific haplodefi-
cient Fgfr1iDEC/+ mice as control mice. We used a murine
B6RV2 lymphoma transplantation model to examine the lym-
phoma growth. Fgfr1iDEC/iDEC mice, but not Fgfr1iDEC/+ mice,
were inhospitable to subcutaneously and intrasplenically injected
B6RV2 LCs, resulting in reduced tumor growth and hepatic colo-
nization (Figures 4G–4K). Therefore, activation of FGFR1 inECs is
required for LCs to establish a protumorigenic vascular niche.
We next crossed Em-Myc mice with Fgfr1iDEC/iDEC and control
mice (Figure 5A) to assess the role of FGFR1 in establishing aLCEC (top panel) and flow cytometry analysis of the clonally derived CD44+
atment (M) comparing CD44+IGF1R+CSF1R+ andCD44IGF1RCSF1R LCs.
splantation into NSG mice; n = 6 and 10 in CD44+IGF1R+CSF1R+ and
or without 50 mg/kg doxorubicin; n = 6–10.
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Figure 2. Angiocrine Effects of Endothelial Jag1 on Notch2 Activation and Propagation of Myc+ Mouse LCs
(A) Expression level of Notch pathway effecter Hey1, Hes1, and Hey2 in LCs.
(B) Approaches to define Notch pathway activation in mouse LCs. Notch1, Notch2, and Hey1 in LCs were silenced by shRNA (shNotch1, shNotch2, and shHey1),
and Notch pathway was blocked by compound E. Cell expansion, Notch activation, colony formation, and hepatic invasiveness were then compared.
(C and D) Quantification (C) and representative image (D) of expansion of LCs coculturedwith ECs (LC+EC) or cultured in serum-freemedium (LC). Srb, scrambled
shRNA; OE Hey1, overexpression of Hey1; Comp E, compound E; n = 4. Scale bar, 25 mm.
(E and F) Notch1 and Notch2 intracellular domains (ICDs) were detected in LCs by immunoblot (E), and Notch2 ICD in LCs was examined by immunostaining (F).
White arrowheads indicate nuclear Notch2 ICD. Scale bar, 10 mm.
(G) ChIP analysis of RBPJ activity in LCs after Notch inhibition. shN1 and shN2 denote shRNA against Notch1 and Notch2, respectively; n = 4.
(legend continued on next page)
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VE-cadherin+ ECs within the lymphoma of control (Myc+
Fgfr1iDEC/+) mice, but not by ECs of Myc+Fgfr1iDEC/iDEC
lymphomas (Figure 5B). Complementary expression of Hey1
was seen in the perivascular LCs of control but not Myc+
Fgfr1iDEC/iDEC mice. As a result, Myc+Fgfr1iDEC/iDEC mice sur-
vived longer than Myc+Fgfr1iDEC/+ controls, owing to reduced
tumor cell proliferation (Figures 5C–5I).
Because ECs promoted the expansion of chemoresistant LCs,
we investigated whether EC-specific deletion of Fgfr1 sensitized
Em-Myc lymphomas to doxorubicin treatment. Survival of Myc+
Fgfr1iDEC/iDEC mice, but not Fgfr1iDEC/+ mice, was prolonged by
chemotherapy (Figure 5I). LCs treated with doxorubicin upregu-
lated FGF4 expression, enabling a vascular niche that confers
chemoresistance to LCs (Figure 5J). Hence, FGFR1-mediated
signaling deploys Jag1 in tumor ECs, establishing a protumori-
genic vascular niche that shelters resident LCs from chemo-
therapy-induced cytotoxicity.
Endothelial Jag1 in Tumor Capillaries Subverts Indolent
LCs to Manifest Aggressive Features
To investigate whether enhanced chemoresistance and inva-
siveness of LCs upon being cocultured with Jag1+ ECs were
due to selective enrichment of an aggressive LC subclone or
bestowing aggressive attributes to indolent LCs by tumorigenic
vascular niche, we cocultured clonally derived CD44
IGF1RCSF1R LCs (triple-negative LCs) with ECs (Figure 6A).
After coculture with ECs, the triple-negative LC progeny ac-
quired 14-fold greater MCF capacity (Figures 6B and 6C).
Immunophenotypic analysis showed that 9.5% of LCs from the
single triple-negative clone are CD44+IGF1R+ after being co-
cultured with EC (Figure 6D). Notably, after EC coculture,
triple-negative LCsweremore lethal to NSGmice following intra-
peritoneal (i.p.) injection (Figure 6E). All of these effects were
attenuated by coculture with Jag1-deficient ECs (Figures 6B–
6E). Therefore, the aggressive lymphoma tumor phenotype is
conferred upon LCs by angiocrine signals emanating from a
tumorigenic vascular microenvironment.
We then assessed tumorigenicity and extranodal invasiveness
of LCs in Jag1iDEC/+ control and Jag1iDEC/iDEC mice (Figure 6F).
LCs transplanted into Jag1iDEC/iDEC mice yielded smaller tumors
than did the same LCs inoculated into Jag1iDEC/+ mice (Figures
6G and 6H; Figure S5A). To test whether host EC Jag1 altered
CD44IGF1RCSF1R LCs in vivo, individual triple-negative
LC clones were injected subcutaneously into Jag1iDEC/iDEC,
Jag1iDEC/+ (Figure 6I), or WTmice (Figure S5B). Following expan-
sion in the recipient mice, transplanted triple-negative LCs
acquired over 6-fold greater triple-positive immunophenotype
and 5-fold higher MCF in Jag1iDEC/+ mice than in Jag1iDEC/iDEC
mice (Figure 6J). Therefore, host EC-derived Jag1 subverts indo-
lent LCs to manifest aggressive phenotypes.(H–K) Aggressive features of LCs were tested after disruption of Notch2-Hey1 pa
into NSGmice (H). Hepatic tumor loadwas examined by H&E staining (I) and fluore
Scale bars, 100 mm in (I) and 1 mm in (K).
(L) Expression of Notch ligands in feeder ECs after coculture with LCs (EC+LC);
(M and N) LCs were cocultured with ECs transduced with Scrambled shRNA (EC
upregulation (M) and fluorescent intensity of RBPJ-driven GFP reporter in LCs (N
(O and P) Representative image (O) and expansion (P) of LCs cultured alone or c
See also Figure S2.DeletionofJag1 inECsofEm-MycMice (Myc+Jag1iDEC/iDEC)
Abolishes de Novo Generation of Aggressive LCs
To assess the lymphoma-promoting role of EC Jag1, we selec-
tively deleted Jag1 in ECs of Em-Myc mice (Myc+Jag1iDEC/iDEC),
using Myc+Jag1iDEC/+ as controls. We then isolated nodal B
cell LCs and assayed for their aggressive attributes (Figure 7A).
During serial methylcellulose culture, LCs from Myc+
Jag1iDEC/iDEC mice had fewer CD44+IGF1R+ LCs and yielded
substantially fewer colonies than LCs from control mice (Figures
7B–7D). LCs derived from Myc+Jag1iDEC/iDEC mice were less
capable in killing the recipient mice and were more sensitive to
doxorubicin compared with LCs isolated from Myc+Jag1iDEC/+
mice (Figures 7E and 7F). LCs from Myc+Jag1iDEC/iDEC mice
also gave rise to fewer and smaller hepatic tumors after intra-
splenic seeding (Figures 7G and 7H). Therefore, the protumori-
genic Jag1+ vascular niche endows aggressive features to
LCs, driving lymphomagenesis, extranodal invasiveness, and
chemoresistance.
Vascular Niche-Derived Jag1Confers Notch-Dependent
Chemoresistance to Myc+ LCs
To unravel the role of EC-derived Jag1 in lymphoma pathogen-
esis and development of chemoresistance, we administered
doxorubicin to Myc+Jag1iDEC/iDEC and control mice (Figures 8A
and 8B). Notch activity was tracked in LCs by crossing Myc+
Jag1iDEC/iDEC mice with transgenic Notch reporter (TNR) mice
expressing GFP upon Notch activation (Butler et al., 2010b).
Genetic ablation of Jag1 in ECs reduced tumor load and
improved survival of Myc+Jag1iDEC/iDEC mice, compared with
controlMyc+Jag1iDEC/+ mice (Figure 8B; Figure S6A). Moreover,
LCs from Myc+Jag1iDEC/iDEC mice were more sensitive to
chemotherapy, manifesting as enhanced survival (64% after
8 months) compared with a median survival of 150 days in
controls. Notch was activated in LCs positioned adjacent to
VE-cadherin+ ECs in control mice, but not in Myc+Jag1iDEC/iDEC
mice (Figures 8C and 8D), indicating that Jag1 supplied by
ECs activate Notch signaling in LCs. The enhanced survival of
Myc+Jag1iDEC/iDEC mice was associated with greater LC death
(Figures 8E and 8F). Notably, when EC Jag1 is intact, a subset
of perivascularly localized LCs with activated Notch signaling
(reported by TNR-GFP cells) was protected from doxorubicin-
induced cell death. Therefore, Jag1-expressing ECs establish
a chemoresistant microenvironment for LCs via juxtacrine Notch
activation (Figure 8G).
To assess whether aberrant EC Jag1 expression could cause
vascular abnormalities that might compromise tumor blood
supply, we examined vascular perfusion in Myc+Jag1iDEC/iDEC
mice by intravenously injecting B4-isolectin to label patent
ECs. The majority of VE-cadherin+ ECs within the lymphoma
were recognized by B4-isolectin. Furthermore, tissue staining
using the hypoxia marker pimonidazole showed little hypoxiathway. Extranodal invasiveness of LCs was examined by intrasplenic injection
scent microscopy (K). Quantification of hepatic tumor load is shown in (J); n = 4.
n = 4.
Srb) and Jag1 shRNA (ECshJag1). Notch activation in LCs was tested by Hey1
); n = 5.
ocultured with ECShJag1 or ECSrb. *p < 0.025; n = 5. Scale bar, 50 mm.
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Figure 3. Influence of Angiocrine Jag1 on Expansion and Aggressive Features of Human B Cell LCs
(A–C) Expression of Hey1 and Jag1 in patient Burkitt’s lymphoma withMYC translocation were examined. VE-cadherin (VE-Cad) was stained to identify ECs (A).
Quantification of Jag1 expression in lymphoma ECs (B) and Hey1 in perivascular LCs (C) is shown. Scale bars, 100 mm and 20 mm in inset.
(D) CD44 and IGF1R expression on human LCs cultured with ECs (LCEC) or with serum (LCSerum).
(E and F) Immunoblot analysis (E) and immunostaining (F) analysis of Notch ICD in LC cultured with serum or with indicated ECs. Srb, Scrambled. Scale bar,
25 mm.
(G and H) Representative image (G) and quantification (H) of colony formation capacity of human LCSerum and LCs cocultured with ECs transduced with
Scrambled (LCEC-srb) or Jag1 shRNA (LCEC-shJag1); n = 4. Scale bar, 100 mm.
(I and J) Representative image of hepatic lymphoma (I) and quantification of tumor colony number burden (J) of human LCEC-srb or LCEC-shJag1 intrasplenically
injected into NSG mice. LCSerum were also injected for comparison. Scale bar, 50 mm.
(legend continued on next page)
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S6D). Therefore, vascular blood supply and oxygen delivery
were not compromised in Myc+Jag1iDEC/iDEC mice. Taken
together, we employed a variety of mouse/human lymphoma
models to demonstrate that angiocrine expression of Jag1
activates lymphoma Notch to promote tumorigenicity without
affecting the passive perfusion function of tumor vasculature.
DISCUSSION
Tumor-initiating cells are believed to acquire aggressive pheno-
types via cell-autonomous mechanisms. Here, we challenge this
paradigm and demonstrate that in certain lymphomas, the protu-
morigenic vascular niche dictates tumor aggressiveness. We
show that tumor ECs convert indolent CD44IGF1RCSF1R
LCs to more aggressive CD44+IGF1R+CSF1R+ LIC-like cells
manifesting greater tumorigenicity, extranodal invasion, and
chemoresistance. The majority of these aggressive tumor fea-
tures were dependent upon FGF4-driven Jag1 expression by
tumor ECs. Disruption of this juxtacrine/angiocrine loop at any
level—FGF4, FGFR1, Jag1, or Notch2—severely diminished
the aggressiveness of both human and murine lymphomas.
Thus, Em-Myc-driven oncogenesis is not sufficient to provoke
aggressive lymphoma behaviors. The LC phenotype is plastic
and is determined by cues emanating from the malignant
vascular niche rather than by cell-autonomous signaling path-
ways alone.
The properties of the malignant vascular niche are co-opted
via activation of FGF4/FGFR1 signaling in tumor ECs. This
signaling induces host ECs to express Jag1 in proximity to
neighboring LCs. Importantly, the FGFR1-Jag1 feed-forward
signaling loop promotes LC chemoresistance and is further
reinforced by chemotherapy administration. In this way, angio-
crine Jag1 functionalizes a chemoresistance niche that activates
Notch signaling in perivascular LCs and spares them from che-
motherapeutics such as doxorubicin. These results suggest a
paradigm of tumor propagation whereby a dynamic neoplasm-
primed tumor microenvironment shelters tumor cells from
chemotherapy and instructively directs them to grow locally
and invade distal organs. Thus, targeting the malignant vascular
niche should sensitize LCs to chemotherapy and improve
outcomes.
Indeed, EC-specific deletion of Fgfr1 or Jag1 in the
Fgfr1iDEC/iDEC and Jag1iDEC/iDEC mice enhanced chemosensitiv-
ity and improved mouse survival by abolishing Notch activation
in Myc+ LCs after doxorubicin treatment. Similarly, in human
lymphoma specimens, we found Jag1 upregulated in tumor
ECs and the Notch pathway activated in perivascular human
LCs, as originally observed in the murine lymphoma models.
These findings highlight the functional interplay between ECs
and tumor cells that depends on the FGF-Notch paracrine/juxta-
crine loop. Upregulation of endothelial Jag1 is central to this loop
because it endows both mouse and human LCs with aggressive(K–N) Inhibition of Notch1, Notch2, and Hey1 was performed in human LCs before
of (M and N) of LCs were determined; n = 4. Scale bars, 1000 mm in (K) and 50 m
(O) Jag1 expression in host ECs within the hepatic lymphoma nodule was assesse
mass in the liver is denoted by a dotted line. Scale bar, 50 mm (20 mm in inset).
See also Figure S3 and Table S2.LC features. Similarly, as-yet unrecognized and distinct angio-
crine pathways are likely activated within the microenvironment
of other tumor types.
Blockade of Jag1 expressed by tumor ECs reduced lym-
phoma progression without compromising perfusion of the
tumor vasculature. Jag1 appeared dispensable for most homeo-
static vascular functions because deletion of endothelial Jag1 in
adult mice caused no excess mortality or morbidity. Thus, inhib-
iting the instructive angiocrine signals from a tumor-primed
vascular niche can effectively target aggressive LC features.
Anti-angiocrine therapeutics need not interfere with tumor perfu-
sion and therefore should not be compromised by tumor hypoxia
and rebound angiogenesis that can lead to paradoxical tumor
growth (Ebos et al., 2009; Pa`ez-Ribes et al., 2009).
Comparative analyses of human and mouse lymphoma tis-
sues suggest that our findings may have clinical relevance.
Jag1 is upregulated in ECs in human lymphoma specimens.
Jag1 upregulation in ECs endows both mouse and human LCs
with aggressive LC features. Whether induced expression of
Jag1 and activation of Notch pathway in human tumor ECs
may also portend poor prognosis is unknown and can only be
determined in double-blind multicenter clinical studies. Based
on our data, we speculate that patients harboring tumors with
the capacity of inducing functional Notch ligands in tumor ECs
may be at higher risk for tumor relapse and chemoresistance
and be treated with more aggressive therapeutic protocols.
Taken together, our findings demonstrate that tumor cells
prime a maladapted vascular niche that reciprocally confers
tumors with aggressive, lethal properties: augmenting tumor
growth, fostering chemoresistance, and promoting extranodal
invasion. Indeed, function of lymphoma-propagating or -initi-
ating cells depends on the protumorigenic state of the vascular
niche and cannot be entirely attributed to cell-autonomous
malignant properties of tumor cells. For example, an authentic
tumor-initiating cell may fail to engraft host tissues with an inhos-
pitable vascular niche, and assays used to identify tumor-initi-
ating cells need to bemodified to account for the activation state
of vascular niche. Similarly, differences in host EC functions may
underlie the tumor tropisms that select common metastatic
sites. This study introduces promising therapeutic approaches
to improve clinical outcomes for patients with aggressive
lymphomas by ejecting LCs from the protumorigenic vascular
niche to limit local tumor growth and extranodal invasion while
sensitizing LCs to chemotherapy.
EXPERIMENTAL PROCEDURES
Transgenic Reporter and Gene-Targeted Animals
Jag1loxP/loxP mice were provided by Dr. Thomas Gridley (Jackson Labora-
tories), and Fgfr1loxp/loxp mice were obtained from Dr. Michael Simons (Yale
University School of Medicine). Generation of inducible EC-specific Fgfr1
knockout mice was carried out as described (Ding et al., 2010, 2011;
Wang et al., 2010). In brief, Fgfr1loxp/loxp or Jag1loxp/loxp mice were bred with
VE-cadherin-CreERT2 (cdh5-PAC-CreERT2) transgenic mice and treatedEC coculture, and EC-dependent expansion (K and L) and hepatic tumor load
m in (M).
d 14 days after intrasplenic injection of human LCs into NSGmice. Lymphoma
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Figure 4. Reciprocal Instigatory Interactions between LCs and Cocultured ECs In Vitro and Host ECs In Vivo
(A) Expression of angiogenic factors VEGF-A, SDF1, FGF2, and FGF4 in mouse and human LCs cocultured with ECs (LC + EC) or in serum-containing medium
(LC); n = 4.
(B–D) ECs transduced with FGFR1 shRNA were stimulated with LC CM. LCs were transduced with Scrambled (LCSrb) and Fgf4 shRNA (LCshFGF4). Jag1 and
FGFR1 protein levels (B) and FGFR1 activation (as determined by phosphorylation of FRS-2) (C) in ECs were examined and quantified (D); n = 4.
(E) After human LCswere transplanted into NSGmice via intrasplenic injection, Jag1 induction in ECs associatedwith hepatic lymphoma nodule was determined.
Lymphoma mass is delineated from normal tissue by a dotted line. Jag1 expression in lymphoma ECs is indicated in the inset. Scale bar, 100 mm and 20 mm in
inset.
(F and G) Schematic representation of generating Fgfr1iDEC/iDEC and control Fgfr1iDEC/+ mice (F) and quantification of growth of subcutaneously injected B6RV2
mouse LCs in these mice (G).
(H–K) B6RV2 lymphoma in the liver was examined in Fgfr1iDEC/iDEC and control mice (H). Histological studies of hepatic tumor load were done with H&E staining (I)
and fluorescent microscopy scan (J) of liver lobe 14 days after intrasplenic injection of LCs. Proliferation of LCs was determined by Ki67 staining (K). Scale bar,
50 mm in (I) and (K) and 1 mm in (J).
See also Figure S4.
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Figure 5. Lymphoma Propagation and Chemoresistance in Em-Myc Mice with EC-Specific Deletion of Fgfr1: Myc+Fgfr1iDEC/iDEC
(A) Generation of Myc+Fgfr1iDEC/iDEC and control Myc+Fgfr1iDEC/+ mice.
(B–D) Expression of Jag1 and Hey1 in lymphoma tissue was determined inMyc+Fgfr1iDEC/iDEC and control mice (B). White arrow indicates expression of Jag1 on
VE-cadherin+ ECs. LC proliferation was tested by Ki67 staining (C). Quantification of Jag1 upregulation in ECs, Hey1, and proliferation marker Ki67 in LCs is
presented in (D); n = 4. Scale bar, 50 mm in B (20 mm in inset).
(E–H) Weight (E and G) and representative images (F and H) of lymph node (E and F) and spleen (G and H) in Myc+Fgfr1iDEC/iDEC and control mice; n = 4.
(I) Survival of Myc+Fgfr1iDEC/iDEC and control mice with or without treatment of 100 mg/kg of doxorubicin every week; n = 5–6.
(J) FGF4 mRNA expression in LCs after treatment of doxorubicin; n = 4.
Cancer Cell
Tumor Vascular Niche Induces Aggressive Lymphomawith tamoxifen to induce EC-specific gene deletion (Fgfr1iDEC/iDEC or Jag1iDEC/
iDEC), as described in Supplemental Experimental Procedures. Lymphoma-
genesis was induced by transgenic Em-driven Myc. Myc+Jag1iDEC/iDEC mice
were crossed with TNR mice in which the activation of the Notch pathway re-
sults in GFP expression. All animal experiments were carried out under the
guidelines of the National Institutes of Health and approved by institutional
animal care and use committee at Weill Cornell Medical College, using age/
weight/genetic background-matched animals.
Human Burkitt’s Lymphoma Tissues/Samples
Burkitt’s lymphoma patient specimens were obtained from Weill Cornell
Medical College. The procedure was approved by the institutional review
board at Weill Cornell Medical College. Patient-related information is identified
in Table S2. Human Burkitt’s LCs without Epstein-Barr-virus infection were
purchased from American Type Culture Collection (ATCC).In Vitro Modeling of Vascular Niche for LC Coculture
To maintain EC survival in serum/growth factor-free conditions without
confounding effects of supplementation with serum, bovine brain extracts
and recombinant angiogenic factors (i.e., VEGF-A, FGF2, epidermal
growth factors, PDGFs, and angiopoietins); primary freshly purified ECs,
such as human umbilical vein ECs; or adult tissue-specific mouse ECs
were transduced with E4ORF1 gene (VeraVec ECs; Angiocrine Bioscience).
VeraVec ECs maintain their native vascular and microvascular attributes
and produce physiological levels of tissue-specific angiocrine factors
(Butler et al., 2010b, 2012; Nolan et al., 2013; Seandel et al., 2008). As
such, VeraVec ECs establish a responsive unbiased vascular niche
model to unequivocally interrogate the role of angiocrine factors in
fostering the homeostasis of tumor cells and LICs. Both Em-Myc mouse
LCs and human Burkitt’s LCs (ATCC) harboring the c-MYC trans-
location were utilized for coculture with VeraVec ECs as described inCancer Cell 25, 350–365, March 17, 2014 ª2014 Elsevier Inc. 359
Figure 6. Acquisition of Aggressive LIC-like Features in LCs by Jag1-Expressing Vascular Niche
(A–E) Aggressive traits of CD44IGF1RCSF1R indolent LC colonies after coculture with ECs was investigated (A). CD44IGF1RCSF1R LC colonies were
cocultured with ECSrb and ECShJag1 and tested for colony-forming capacity (B and C), CD44 and IGF1R expression (D), and lethality in NSGmice after injection of
5 3 103 indicated LCs (E).
(F) Different LC colonies were transplanted into mice with EC-specific deletion of Jag1 (Jag1iDEC/iDEC). Jag1iDEC/+ mice were used as control.
(G and H) Propagation of CD44+IGF1R+CSF1R+ LCs in Jag1iDEC/iDEC and control mice was determined after subcutaneous (G) and intrasplenic transplantation.
Representative H&E staining of liver is shown in (H); n = 4. Scale bar, 50 mm.
(I and J) Acquisition of aggressive LIC features in CD44IGF1RCSF1R LCs after transplantation to control and Jag1iDEC/iDEC mice. LCs were isolated at day 28
after subcutaneous injection from enlarging tumormass and analyzed for CD44, IGF1R, andCSF1R (I) and serial colony formation capacity (J). Each derived clone
was injected into three mice.
See also Figure S5.
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Figure 7. Generation of Invasive and Chemoresistant Triple-Positive LC Subpopulation in Myc+ Mice with Conditional Deletion of Jag1 in
ECs: Myc+Jag1iDEC/iDEC
(A) Analysis of aggressive attributes of LCs from Myc+Jag1iDEC/iDEC and control Myc+Jag1iDEC/+ mice. FACS, fluorescence-activated cell sorting.
(B) Percentage of CD44+IGF1R+ LC subset in Myc+Jag1iDEC/iDEC and control mice.
(C and D) Colony-forming capacity of LCs. Five clones isolated fromMyc+ mice were picked for each passage. Representative images (C) and quantification of
colony (D) are shown. Scale bar, 500 mm.
(E) Lethality of LCs from control (left) and Myc+Jag1iDEC/iDEC (right) mice after limiting dilution transplantation into NSG mice.
(F) Survival of NSG mice injected with 105 indicated LCs with or without treatment of 50 mg/kg doxorubicin; n = 5–8.
(G and H) Representative image (G) and quantification of tumor colony number (H) of hepatic tumor in NSG mice after injection of LCs. Scale bar, 1mm.
Cancer Cell
Tumor Vascular Niche Induces Aggressive LymphomaSupplemental Experimental Procedures. For simplicity, we refer to VeraVec
ECs as ECs.
To investigate the angiocrine contribution of vascular niche to aggres-
siveness of LCs/LICs, Jag1 shRNA or scrambled shRNA (Open Biosystems)was used to knock down Jag1 in ECs. Experimental procedures of
shRNA knockdown of Notch pathway (Notch1, Notch2, and Hey1) in LCs
and Notch ligand Jag1 in ECs are described in Supplemental Experimental
Procedures.Cancer Cell 25, 350–365, March 17, 2014 ª2014 Elsevier Inc. 361
Figure 8. Chemoresistance of Lymphoma in Myc+Jag1iDEC/iDEC and Control Myc+Jag1iDEC/+ Mice
(A) To test the role of angiocrine Jag1 in stimulating chemoresistance, control and Myc+Jag1iDEC/iDEC mice were treated with doxorubicin at 100 mg/kg once a
week for 4 consecutive weeks.
(B) Survival rate of Myc+Jag1iDEC/iDEC and control mice. Chemo indicates mouse group treated with 100 mg/kg doxorubicin.
(C and D) Jag1 expression in VE-cadherin+ ECs and Notch activation (GFP expression) in LCs were measured with or without chemotherapy (C). Quantification of
GFP intensity is shown (D). Compound E was injected into control mice to compare the degree of Notch inhibition; n = 4. Scale bar, 50 mm.
(E and F) Terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining image (E) and quantification of TUNEL+ cells (F) in the
lymphoma of Myc+ mice after chemotherapy; n = 4. Scale bar, 50 mm.
(G) Angiocrine Jag1 activates Hey1 to stimulate the emergence of LCs exhibiting aggressive LIC features. Expanding LCs reciprocally activate FGFR1 on ECs and
induce Jag1 upregulation, further reinforcing Jag1-mediated angiocrine support of aggressive LCs with LIC attributes.
See also Figure S6.
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To monitor tumor propagation in vivo, 5 3 105 human LCs or 1 3 105
murine Em-Myc LCs were injected i.p., or 2 3 106 LCs were injected
subcutaneously into immunodeficient NSG mice and mice with the indicated
genetic backgrounds. A liver-seeding model via intrasplenic transplantation362 Cancer Cell 25, 350–365, March 17, 2014 ª2014 Elsevier Inc.of LCs was performed as described (Ding et al., 2010). Briefly, the mice
were anesthetized, and 5 3 105 mCherry-labeled human LCs or 1 3 105
mouse LCs were injected into the parenchyma of the spleen. Splenectomy
was carried out after the injection. The mice were sacrificed 14 days after
intrasplenic transplantation, and hepatic tumor load was analyzed by
Cancer Cell
Tumor Vascular Niche Induces Aggressive Lymphomahematoxylin and eosin (H&E) staining and immunofluorescence whole scan
of liver lobe.
g-secretase inhibitor compound E was utilized to abolish Notch pathway
activation in LCs. LCs were incubated with 1 mM compound E. For in vivo
Notch inhibition, compound E was i.p. injected to mice at 2 mg/kg. Notch2
activation was also determined as described in Supplemental Experimental
Procedures.
Flow Cytometric Analysis of LCs
For flow cytometry analysis, LCs were filtered through a 30 mm strainer, pre-
blocked with Fc block (CD16/CD32; BD Biosciences), and then incubated
with the primary antibodies CD44, CD19, and B220 (eBiosciences); IGF1R
(Abcam); and Notch1 and Notch2 (Biolegend). Primary antibodies were
conjugated to Alexa Fluor dyes using antibody labeling kits (Invitrogen)
following the instructions of the manufacturer. GFP-expressing cells were
detected by their own fluorescence, as described in Supplemental Experi-
mental Procedures.
Immunofluorescent Staining
For immunofluorescence study, cryopreserved sections were incubated with
antibodies to mouse VE-Cadherin (R&D Systems), Jag1 (Abcam), and Ki67
(Dako) supplemented with 10% normal donkey serum/1% BSA/0.1% Tween
20, followed by incubation with fluorophore-conjugated second antibodies
(Jackson ImmunoResearch). Images were captured on AxioVert LSM710
microscope (Zeiss).
Methylcellulose Colony Assay
Mouse and human LCs formed colonies upon serum culture (LCSerum) or EC
coculture (LCEC). Single colonies of LCSerum and LCEC were dispersed in
methylcellulose. Colonies formed were randomly picked and serially
passaged. Colony number was quantified upon each serial passage.
Statistical Analysis of Data
All data are presented as means ± SEM. Comparisons between different
groups were made using Student’s t test and ANOVA. Statistical significance
was considered as p < 0.05.
ACCESSION NUMBERS
Themicroarray data are deposited at Gene Expression Omnibus under acces-
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